CMC & ManufacturingLast reviewed May 2026

Technology Transfer(Tech Transfer)

The documented process of moving manufacturing technology and knowledge from one site or party to another to enable production at the new location.

Usage Examples

The tech transfer from CMO A to CDMO B required three validation batches and a prior approval supplement.
Analytical method transfer was completed via co-validation at both sites.
A tech transfer gap in cleaning validation delayed commercial launch by 4 months.

What is Tech Transfer?

Technology transfer is the structured process of moving manufacturing processes, analytical methods, and associated knowledge from one site or party to another — most commonly from development to commercial manufacturing, from an innovator to a CDMO, or between manufacturing sites. A successful tech transfer reproduces product quality and process performance at the receiving site with minimal variability from the sending site.

ICH Q10 and ICH Q12 frame tech transfer as a Pharmaceutical Quality System activity spanning product lifecycle. The tech transfer package typically includes process description, equipment specifications, analytical methods and validation, specifications, manufacturing procedures, deviations history, stability data, and critical process knowledge. Comparability protocols, engineering batches, and validation batches demonstrate that the receiving site produces material equivalent to the sending site.

Tech transfer failures are a leading cause of supply delays and commercial disruption. Common failure modes include inadequate process knowledge transfer, equipment differences not addressed, insufficient validation data, analytical method transfer gaps, and incomplete documentation. Regulatory consequences include delayed approvals (during PAI), CBE-30 or PAS filings for site changes, and potential supply interruption.

Regulatory Context

This term appears most often in cmc & manufacturing workflows where submission quality, regulatory evidence, and audit readiness depend on consistent language. It is commonly referenced alongside ICH Q10, ICH Q12, ICH Q7.

FDAICHHealth Canada

When This Matters

The tech transfer from CMO A to CDMO B required three validation batches and a prior approval supplement.
Analytical method transfer was completed via co-validation at both sites.
A tech transfer gap in cleaning validation delayed commercial launch by 4 months.

Common Mistakes

Failing to align CMC change narratives with current CFR/ICH expectations.
Submitting incomplete control strategy documentation.
Separating manufacturing and regulatory review cycles too late in execution.

Related Regulations

ICH Q10ICH Q12ICH Q7

How to Execute a Pharmaceutical Technology Transfer

Move manufacturing technology and process knowledge from one site to another while preserving product quality and regulatory compliance.

1
Scope the transfer
Define what transfers: drug substance process, drug product process, analytical methods, cleaning validation, stability program. Sites, quantities, commercial vs. clinical intent. Document in a Transfer Plan signed by sending and receiving sites.
2
Assemble the tech transfer package
Compile process description, equipment specifications, critical parameters, analytical methods and their validation, specifications, batch records, deviations history, stability data, and tacit knowledge captured from senior operators.
3
Assess gaps at receiving site
Map equipment, scale, raw material supply, and analytical capability at the receiving site against the sending site. Identify gaps requiring engineering batches, equipment procurement, or analytical method re-validation.
4
Execute engineering and validation batches
Run 1-3 engineering batches to confirm process fits at receiving site, then 3 process performance qualification (PPQ) batches for formal validation. Each batch is evaluated for process parameters and quality attributes matching the sending site baseline.
5
Transfer and validate analytical methods
Co-validate analytical methods at both sites (typically parallel testing of common samples). Document equivalence via acceptance criteria defined in the transfer protocol.
6
File regulatory submission
Prior Approval Supplement (FDA) or Type II Variation (EU) for commercial products. CBE-30 may apply to lower-risk changes. File with validation data, analytical transfer results, and updated Module 3 content.
7
Pass Pre-Approval Inspection
FDA PAI or equivalent international inspection confirms receiving site GMP readiness. Close any observations promptly. Approval enables commercial production transition.

Frequently Asked Questions

Yes, for commercial products. Adding a new manufacturing site typically requires a Prior Approval Supplement (PAS) at FDA; some changes may qualify for CBE-30. EU uses variation procedures (typically Type II). The specific filing depends on what changes (site, scale, process) and the product-specific risk.

Typical timeline from initiation to commercial readiness: 12-24 months for a drug substance transfer, 9-18 months for a drug product transfer. Gene and cell therapy transfers take longer due to complexity. Active timeline depends on validation batches required, analytical method transfer complexity, and regulatory filing duration.

Inadequate process knowledge transfer — the sending site's tacit expertise (troubleshooting, process nuances, equipment behavior) doesn't make it into formal documentation. Mitigation: structured knowledge capture, senior operator involvement in transfer, and iterative process fitting at the receiving site during engineering batches.